FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:418-420 July 24, 2008 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Maheswaran, S. PubMed Citation

The treatment of non–small-cell lung cancer has made limited but clinically significant progress during the past two decades of clinical research. Through carefully designed clinical trials, investigators have identified several chemotherapeutic drugs to combat this disease. Many questions have been asked and answered. Which combinations work best? How frequently should they be given and for how long? And which patients should be treated?¹ Nonetheless, such advances have been limited, and the prognosis for patients with advanced disease remains grim.

Despite the modest results achieved with conventional cytotoxic chemotherapeutic agents, the past several decades of basic cancer research have started to . . . [Full Text of this Article]

Source Information

This article (10.1056/NEJMe0804521) was published at www.nejm.org on July 2, 2008.

From the Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.

This article has been cited by other articles:

• (2008). Detecting EGFR Mutations in Circulating Lung Cancer Cells. JWatch Oncology and Hematology 2008: 1-1 [Full Text]